Lucina Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Lucina Biosciences is a private, pre-revenue biotech firm pioneering the development of placental tissue-derived allografts. The company leverages state-of-the-art processing facilities to create biologic products intended to enhance clinical outcomes in wound care and tissue repair. Led by a small, experienced team, Lucina's strategy is built on a foundation of stringent regulatory compliance and scientific innovation within the growing regenerative medicine market. Its primary commercial asset appears to be the Procenta® placental derived allograft.

Wound CareRegenerative Medicine

Technology Platform

Proprietary processing of human placental tissue to create biologically active allografts under cGTP/cGMP standards.

Opportunities

The company operates in the high-growth advanced wound care and regenerative medicine market, driven by aging demographics and chronic diseases.

Its focus on stringent quality and compliance is a key differentiator in a regulated space.

Successfully commercializing its Procenta® allograft could position it as an acquisition target for larger medical device or biotech firms.

Risk Factors

Lucina faces intense competition from established players with greater resources and clinical data.

Regulatory risk is high, as any failure to maintain cGTP/cGMP compliance could halt operations.

As a likely pre-profit company, it is vulnerable to cash flow constraints and may require additional financing to scale.

Competitive Landscape

Lucina competes in the placental tissue allograft market against larger, publicly traded companies like MiMedx and Organogenesis, which have broader product portfolios and established sales forces. Differentiation will rely on product quality, cost-effectiveness, and building clinical evidence. The market is competitive but large enough for niche players with strong execution.

More companies in Biologics / Biosimilars →More companies in United States →